Drug updated on 11/13/2023
|Injection (subcutaneous: 3.5 mg)
| Ongoing and
- For treatment of adult patients with multiple myeloma.
- For treatment of adult patients with mantle cell lymphoma.
Product Monograph / Prescribing Information
|Velcade (bortezomib) Prescribing Information
|Takeda Pharmaceuticals America, Inc. Lexington, MA
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
|Journal of the National Comprehensive Cancer Network
|European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.
|Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.
|Cancer Care Ontario